^
Phase 1/2
Sanofi
Active, not recruiting
Last update posted :
09/23/2021
Initiation :
07/23/2014
Primary completion :
03/31/2022
Completion :
03/31/2022
CEACAM5
|
CEACAM5 positive • CEACAM5 expression
|
tusamitamab ravtansine (SAR408701)
Phase 2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/23/2021
Initiation :
02/12/2019
Primary completion :
09/17/2024
Completion :
09/17/2024
HER-2 • PD-L1 • ER • PGR
|
Keytruda (pembrolizumab) • lenvatinib
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/23/2021
Initiation :
12/30/2020
Primary completion :
12/31/2024
Completion :
12/31/2024
PD-L1
|
HER-2 negative
|
Keytruda (pembrolizumab) • 5-fluorouracil • lenvatinib • capecitabine • oxaliplatin • leucovorin calcium
Phase 1
Bayer
Recruiting
Last update posted :
09/23/2021
Initiation :
07/02/2020
Primary completion :
07/24/2025
Completion :
07/24/2027
HER-2
|
HER-2 amplification • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
BAY2701438 • BAY2701439
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
09/23/2021
Initiation :
09/28/2021
Primary completion :
01/31/2025
Completion :
12/31/2025
PD-L1
|
HER-2 positive
|
Keytruda (pembrolizumab) • Anktiva (inbakicept) • PD-L1.t-haNK
Phase 1/2
Hoffmann-La Roche
Recruiting
Last update posted :
09/23/2021
Initiation :
10/13/2017
Primary completion :
02/08/2025
Completion :
02/08/2025
HER-2 • PD-L1 • TIGIT
|
HER-2 negative • HER-2 expression
|
cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • Cyramza (ramucirumab) • leucovorin calcium • tiragolumab (MTIG7192A) • pegvorhyaluronidase alfa (PEGPH20) • Tradjenta (linagliptin) • motixafortide (BL-8040)
Phase 2
Taiho Oncology, Inc.
Recruiting
Last update posted :
09/23/2021
Initiation :
08/31/2020
Primary completion :
06/01/2022
Completion :
10/01/2022
FGFR2
|
FGFR2 amplification
|
futibatinib (TAS 120)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
01/13/2017
Primary completion :
08/01/2022
Completion :
08/01/2022
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1
Incyte Corporation
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
09/24/2018
Primary completion :
09/30/2021
Completion :
09/30/2021
HAVCR2
|
INCAGN2390
Phase 3
Amgen
Not yet recruiting
Last update posted :
09/22/2021
Initiation :
12/06/2021
Primary completion :
01/06/2025
Completion :
01/06/2025
FGFR2
|
FGFR2 overexpression • FGFR2b overexpression
|
oxaliplatin • bemarituzumab (FPA-144)
Phase 1
EMD Serono Research & Development Institute, Inc.
Recruiting
Last update posted :
09/22/2021
Initiation :
01/13/2021
Primary completion :
07/15/2023
Completion :
03/27/2024
EGFR • MSI • MUC1
|
MSI-H/dMMR • EGFR expression • MUC1 expression
|
M1231
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
09/22/2021
Initiation :
05/01/2019
Primary completion :
07/01/2023
Completion :
12/01/2024
HER-2 • ER • PGR
|
HER-2 negative
|
Yervoy (ipilimumab) • izuralimab (XmAb23104)
Phase 1a/1b
OncoC4, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
09/16/2020
Primary completion :
12/31/2022
Completion :
12/31/2023
EGFR
|
EGFR mutation
|
Keytruda (pembrolizumab) • Tagrisso (osimertinib) • ONC-392
Phase 1
Seagen Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
01/18/2021
Primary completion :
12/31/2022
Completion :
12/31/2023
HER-2
|
HER-2 negative
|
SGN-STNV
Phase 2
Andrew Hendifar, MD
Recruiting
Last update posted :
09/21/2021
Initiation :
07/28/2021
Primary completion :
02/01/2024
Completion :
02/01/2024
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
Phase 2
Astellas Pharma Global Development, Inc.
Active, not recruiting
Last update posted :
09/21/2021
Initiation :
06/29/2018
Primary completion :
07/31/2022
Completion :
02/28/2023
PD-L1 • CLDN18
|
PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • zolbetuximab (IMAB362)
Phase 1/2
Elucida Oncology
Recruiting
Last update posted :
09/21/2021
Initiation :
09/13/2021
Primary completion :
03/15/2024
Completion :
03/15/2025
FOLR1
|
ELU001
Phase 2
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
03/09/2020
Primary completion :
07/31/2023
Completion :
07/31/2023
BRAF • ALK • ER • PGR
|
PD-L1 expression • HER-2 positive • EGFR mutation • BRAF mutation • ER positive • HER-2 negative • ER negative • PGR negative
|
Padcev (enfortumab vedotin)
Phase N/A
Eli Lilly and Company
No Longer Available
Last update posted :
09/21/2021
HER-2
|
EGFR positive
|
cisplatin • paclitaxel • Cyramza (ramucirumab)
Phase 1
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
09/21/2021
Initiation :
02/28/2022
Primary completion :
06/01/2023
Completion :
06/01/2023
PD-L1
|
Keytruda (pembrolizumab) • lenvatinib
Phase 1
Pfizer
Recruiting
Last update posted :
09/20/2021
Initiation :
11/13/2019
Primary completion :
01/06/2024
Completion :
01/06/2024
PD-1
|
sasanlimab (PF-06801591) • PF-06940434
Phase 1/2
Sumitomo Dainippon Pharma Oncology, Inc
Completed
Last update posted :
09/20/2021
Initiation :
01/01/2014
Primary completion :
03/01/2019
Completion :
11/01/2019
KRAS
|
Avastin (bevacizumab) • capecitabine • oxaliplatin • irinotecan • Stivarga (regorafenib) • leucovorin calcium • napabucasin (BBI608) • fluorouracil topical
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
09/20/2021
Initiation :
07/25/2017
Primary completion :
07/02/2020
Completion :
06/03/2022
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil
Phase 1
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/20/2021
Initiation :
12/01/2011
Primary completion :
06/14/2021
Completion :
11/23/2023
BRAF • RNF43
|
BRAF mutation • RNF43 mutation
|
spartalizumab (PDR001) • WNT974
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
09/20/2021
Initiation :
11/03/2016
Primary completion :
11/01/2022
Completion :
11/01/2022
HER-2
|
HER-2 amplification • HER-2 overexpression
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin
Phase 2
Adaptimmune
Not yet recruiting
Last update posted :
09/20/2021
Initiation :
09/01/2021
Primary completion :
04/01/2023
Completion :
10/01/2038
HLA-A • MAGEA4
|
MAGEA4 expression
|
ADP-A2M4CD8
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
03/05/2021
Primary completion :
03/31/2026
Completion :
03/31/2026
CD4
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
Phase 1
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/17/2021
Initiation :
07/11/2018
Primary completion :
11/18/2024
Completion :
11/18/2024
HER-2
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • lenvatinib • pemetrexed • MK-4830
Phase 1/2
LaNova Medicines Limited
Not yet recruiting
Last update posted :
09/17/2021
Initiation :
09/30/2021
Primary completion :
04/10/2023
Completion :
05/05/2024
MSI • CLDN18
|
MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive
|
LM302
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/16/2021
Initiation :
02/28/2020
Primary completion :
02/21/2026
Completion :
02/21/2026
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • oxaliplatin • leucovorin calcium • Levofolinate • levoleucovorin calcium
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/16/2021
Initiation :
07/28/2021
Primary completion :
12/29/2025
Completion :
12/29/2025
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • lenvatinib • oxaliplatin • Levofolinate • levoleucovorin calcium
Phase 1
Herbert Lyerly
Recruiting
Last update posted :
09/15/2021
Initiation :
07/13/2020
Primary completion :
12/01/2022
Completion :
12/01/2023
ERBB3
|
ERBB3 expression
Phase 2
Sichuan Cancer Hospital and Research Institute
Recruiting
Last update posted :
09/15/2021
Initiation :
04/01/2021
Primary completion :
04/01/2022
Completion :
03/31/2023
CD8
|
CD8 positive
|
carboplatin • paclitaxel
Phase 1
Arcus Biosciences, Inc.
Recruiting
Last update posted :
09/15/2021
Initiation :
03/19/2021
Primary completion :
06/01/2023
Completion :
12/01/2023
PD-L1
|
PD-L1 expression • PD-L1 overexpression
|
zimberelimab (AB122) • AB308
Phase 2
AstraZeneca
Recruiting
Last update posted :
09/15/2021
Initiation :
08/20/2021
Primary completion :
12/28/2022
Completion :
08/31/2023
HER-2
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 1
Conjupro Biotherapeutics, Inc.
Not yet recruiting
Last update posted :
09/15/2021
Initiation :
02/15/2022
Primary completion :
02/15/2025
Completion :
03/15/2025
CLDN18
|
SYSA1801
Phase 1
Seagen Inc.
Recruiting
Last update posted :
09/15/2021
Initiation :
05/29/2020
Primary completion :
12/31/2022
Completion :
03/31/2023
TIGIT
|
sasanlimab (PF-06801591) • SGN-TGT
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
09/14/2021
Initiation :
03/12/2021
Primary completion :
09/15/2022
Completion :
04/30/2025
HER-2
|
HER-2 positive
|
Herceptin (trastuzumab) • Tecentriq (atezolizumab) • capecitabine • oxaliplatin
Phase 1
Amgen
Recruiting
Last update posted :
09/14/2021
Initiation :
01/20/2020
Primary completion :
11/26/2025
Completion :
11/26/2025
BRAF • KRAS • NRAS • MSI
|
BRAF V600E • MSI-H/dMMR • BRAF V600
|
AMG 199
Phase 1a/1b
PsiOxus Therapeutics Ltd
Not yet recruiting
Last update posted :
09/14/2021
Initiation :
09/27/2021
Primary completion :
10/06/2022
Completion :
12/15/2022
MSI
|
MSI-H/dMMR
|
Opdivo (nivolumab) • NG-641
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/13/2021
Initiation :
04/11/2018
Primary completion :
12/31/2026
Completion :
12/31/2026
ALB
|
PD-L1 expression
|
Keytruda (pembrolizumab) • decitabine
Phase 1
Ascentage Pharma Group Inc.
Recruiting
Last update posted :
09/13/2021
Initiation :
05/27/2019
Primary completion :
05/01/2022
Completion :
05/01/2023
ALK • ROS1
|
ALK positive • ROS1 positive • ROS1 fusion • ALK-ROS1 fusion
|
APG-2449
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/13/2021
Initiation :
06/09/2020
Primary completion :
05/30/2026
Completion :
01/30/2027
HER-2
|
HER-2 overexpression
|
paclitaxel • capecitabine
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/13/2021
Initiation :
09/17/2020
Primary completion :
09/16/2025
Completion :
09/16/2025
MSI
|
MSI-H/dMMR
Phase 3
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Recruiting
Last update posted :
09/13/2021
Initiation :
12/01/2016
Primary completion :
12/01/2021
Completion :
12/01/2021
HER-2
|
HER-2 negative
|
cisplatin • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • leucovorin calcium
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/13/2021
Initiation :
06/05/2017
Primary completion :
10/01/2025
Completion :
10/01/2027
HER-2
|
HER-2 overexpression
|
cisplatin • mitomycin
Phase 1b
Janssen Research & Development, LLC
Recruiting
Last update posted :
09/10/2021
Initiation :
11/10/2020
Primary completion :
04/03/2023
Completion :
12/29/2024
EGFR • MET
|
Lispro-PH20 (insulin lispro/rHuPH20) • amivantamab SC (Ami-LC)
Phase 3
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
09/10/2021
Initiation :
06/21/2018
Primary completion :
02/28/2022
Completion :
12/31/2023
HER-2 • CLDN18
|
HER-2 negative • CLDN18.2 expression
|
5-fluorouracil • oxaliplatin • leucovorin calcium • zolbetuximab (IMAB362)
Phase N/A
Stanford University
Recruiting
Last update posted :
09/10/2021
Initiation :
04/01/2011
Primary completion :
12/01/2022
Completion :
12/01/2025
CDH1
|
CDH1 mutation
Phase 1
Carisma Therapeutics Inc
Recruiting
Last update posted :
09/10/2021
Initiation :
02/02/2021
Primary completion :
02/01/2022
Completion :
02/01/2023
HER-2
|
HER-2 positive • HER-2 overexpression
|
CT-0508
Phase 1b/2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/10/2021
Initiation :
10/28/2020
Primary completion :
10/15/2025
Completion :
10/15/2025
HER-2 • PD-L1 • ER • PGR
|
HER-2 positive • HER-2 negative
|
Keytruda (pembrolizumab) • Cavatak (CVA21)
Phase 1
Leap Therapeutics, Inc.
Completed
Last update posted :
09/10/2021
Initiation :
05/05/2014
Primary completion :
07/19/2019
Completion :
01/11/2021
PD-L1
|
Keytruda (pembrolizumab) • paclitaxel • DKN-01
Phase 1b/2
Sumitomo Dainippon Pharma Oncology, Inc
Recruiting
Last update posted :
09/10/2021
Initiation :
12/14/2017
Primary completion :
08/01/2023
Completion :
02/01/2024
MSI • HLA-A
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
Phase 3
Daiichi Sankyo, Inc.
Recruiting
Last update posted :
09/10/2021
Initiation :
05/21/2021
Primary completion :
04/15/2024
Completion :
11/15/2024
HER-2
|
HER-2 positive • HER-2 amplification
|
paclitaxel • Cyramza (ramucirumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 1
The Methodist Hospital Research Institute
Recruiting
Last update posted :
09/09/2021
Initiation :
08/03/2018
Primary completion :
10/31/2021
Completion :
01/28/2022
BRAF • PD-L1 • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab)
Phase 3
BeiGene
Active, not recruiting
Last update posted :
09/09/2021
Initiation :
01/26/2018
Primary completion :
12/01/2020
Completion :
09/01/2021
PD-L1
|
PD-L1 expression
|
paclitaxel • docetaxel • irinotecan • Baize’an (tislelizumab)
Phase N/A
Mayo Clinic
Enrolling by invitation
Last update posted :
09/08/2021
Initiation :
09/24/2020
Primary completion :
02/28/2022
Completion :
06/30/2022
CXCL8
Phase 1
Boehringer Ingelheim
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
02/23/2018
Primary completion :
10/05/2021
Completion :
11/09/2021
EGFR • ALK
|
PD-L1 expression • ALK rearrangement
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/08/2021
Initiation :
02/01/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
HER-2 • ER • PGR • ATM
|
HER-2 negative • ATM mutation • ATM expression
|
cisplatin • gemcitabine • elimusertib (BAY1895344) • liposomal gemcitabine (FF-10832)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
02/01/2016
Primary completion :
11/08/2018
CD4
|
ropidoxuridine (IPdR)
Phase 1
Boehringer Ingelheim
Not yet recruiting
Last update posted :
09/08/2021
Initiation :
09/22/2021
Primary completion :
03/15/2024
Completion :
01/02/2025
FAP
|
BI 765179 • ezabenlimab (BI 754091)
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
09/03/2021
Initiation :
06/30/2020
Primary completion :
07/01/2022
Completion :
07/01/2022
HER-2 • TP53 • MSI
|
TP53 mutation • HER-2 positive • MSI-H/dMMR
|
irinotecan • berzosertib (M6620)
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
09/03/2021
Initiation :
06/25/2021
Primary completion :
08/20/2024
Completion :
08/20/2024
CD8 • PD-1 • LAG3 • HAVCR2 • CD4
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • RO7121661 • RO7247669
Phase 2
National Cancer Center Hospital East
Not yet recruiting
Last update posted :
09/03/2021
Initiation :
09/01/2021
Primary completion :
03/31/2024
Completion :
03/31/2025
HER-2
|
HER-2 overexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 1
Amgen
Recruiting
Last update posted :
09/02/2021
Initiation :
06/29/2020
Primary completion :
09/21/2025
Completion :
09/21/2025
CLDN18
|
CLDN18.2 positive
|
AMG 910
Phase 1/2
Shanghai Miracogen Inc.
Recruiting
Last update posted :
09/02/2021
Initiation :
05/24/2021
Primary completion :
12/01/2022
Completion :
08/01/2023
HER-2
|
HER-2 positive
|
MRG002
Phase 4
Hecheng Li M.D., Ph.D
Recruiting
Last update posted :
09/02/2021
Initiation :
11/10/2020
Primary completion :
12/01/2023
Completion :
12/01/2028
IL6 • TNFA
Phase 1/2
Bavarian Nordic
Recruiting
Last update posted :
09/02/2021
Initiation :
08/10/2020
Primary completion :
12/01/2022
Completion :
12/01/2024
ER • PGR
|
HER-2 positive • HER-2 amplification • HER-2 negative • HER-2 expression • ER positive + PGR positive • PGR positive
|
TAEK-VAC-HerBy vaccine
Phase 1
Ambrx, Inc.
Recruiting
Last update posted :
09/02/2021
Initiation :
03/20/2018
Primary completion :
08/01/2022
Completion :
03/01/2023
HER-2
|
HER-2 overexpression • HER-2 mutation
|
ARX788
Phase 2
Hutchison Medipharma Limited
Recruiting
Last update posted :
09/02/2021
Initiation :
07/27/2021
Primary completion :
12/01/2024
Completion :
03/01/2025
MET
|
MET amplification
|
Orpathys (savolitinib)
Phase 2
Wan He
Not yet recruiting
Last update posted :
09/02/2021
Initiation :
09/01/2021
Primary completion :
09/30/2023
Completion :
09/30/2024
PD-L1 • MSI
|
MSI-H/dMMR
|
Tuoyi (toripalimab)
Phase N/A
xCures
Available
Last update posted :
09/02/2021
BRAF • NRAS • HRAS
|
BRAF mutation • ER mutation • HRAS mutation
|
ulixertinib (BVD-523)
Phase 1
Keythera Pharmaceuticals (Australia) Pty Ltd
Recruiting
Last update posted :
09/01/2021
Initiation :
03/09/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
PD-L1 • CD8 • IFNG • CXCL10 • TNFA
|
PD-L1 expression
|
Tecentriq (atezolizumab) • KF-0210
Phase 3
AstraZeneca
Recruiting
Last update posted :
09/01/2021
Initiation :
10/19/2020
Primary completion :
06/30/2025
Completion :
10/30/2026
PD-L1
|
PD-L1 expression
|
cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine
Phase 1
Genentech, Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
06/06/2018
Primary completion :
06/29/2023
Completion :
06/30/2023
HER-2
|
HER-2 positive • HER-2 expression
|
cisplatin • runimotamab (BTRC4017A)
Phase 2
Lytix Biopharma AS
Recruiting
Last update posted :
09/01/2021
Initiation :
06/01/2021
Primary completion :
12/31/2022
Completion :
08/31/2023
BRAF • MSI • BRCA
|
PD-L1 expression • MSI-H/dMMR • BRAF mutation • BRCA mutation
|
Keytruda (pembrolizumab) • cisplatin • Oncopore (ruxotemitide)
Phase 1/2
Yonsei University
Not yet recruiting
Last update posted :
08/31/2021
Initiation :
10/01/2021
Primary completion :
12/31/2022
Completion :
05/31/2023
HER-2 • BRCA2 • BRCA1 • HRD • CDK12 • MLH1 • MSH6 • MSH2 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
Phase 3
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
08/31/2021
Initiation :
06/04/2008
Primary completion :
09/24/2012
Completion :
12/31/2022
HER-2
|
HER-2 positive
|
lapatinib • capecitabine • oxaliplatin
Phase 1b
Rahul Aggarwal
Recruiting
Last update posted :
08/30/2021
Initiation :
08/20/2018
Primary completion :
05/31/2023
Completion :
05/31/2023
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • abexinostat (CG-781)
Phase 3
Australasian Gastro-Intestinal Trials Group
Recruiting
Last update posted :
08/30/2021
Initiation :
06/01/2021
Primary completion :
06/01/2025
Completion :
06/01/2026
HER-2
|
HER-2 positive
|
Opdivo (nivolumab) • docetaxel • Abraxane (albumin-bound paclitaxel) • irinotecan • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • colchicine
Phase 1/2
Bicycle Tx Limited
Recruiting
Last update posted :
08/30/2021
Initiation :
07/17/2020
Primary completion :
06/01/2023
Completion :
06/01/2023
EGFR • ALK • NECTIN4
|
NECTIN4 expression
|
Opdivo (nivolumab) • BT8009
Phase 1
Mayo Clinic
Recruiting
Last update posted :
08/30/2021
Initiation :
02/13/2020
Primary completion :
07/31/2022
Completion :
07/31/2022
EGFR • BRAF • PD-L1 • ALK • MSI
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • Odomzo (sonidegib)
Phase 1/2
Astellas Pharma Global Development, Inc.
Not yet recruiting
Last update posted :
08/30/2021
Initiation :
09/30/2021
Primary completion :
01/31/2026
Completion :
01/31/2028
PD-L1 • CTAG1B • SSX1
|
CTAG1B expression
|
Keytruda (pembrolizumab) • ASP0739
Phase 1/2
The First Affiliated Hospital of Zhengzhou Univ...
Not yet recruiting
Last update posted :
08/27/2021
Initiation :
10/01/2021
Primary completion :
04/01/2023
Completion :
10/01/2024
HER-2
|
HER-2 negative
|
oxaliplatin • Tuoyi (toripalimab) • Elunate (fruquintinib)
Phase 2/3
ALX Oncology Inc.
Not yet recruiting
Last update posted :
08/27/2021
Initiation :
08/01/2021
Primary completion :
07/01/2026
Completion :
08/01/2028
HER-2
|
HER-2 overexpression
|
Herceptin (trastuzumab) • paclitaxel • Cyramza (ramucirumab) • evorpacept (ALX148)
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
08/27/2021
Initiation :
12/30/2010
Primary completion :
12/23/2019
HER-2
|
HER-2 positive • HER-2 expression
|
Herceptin (trastuzumab) • carboplatin • paclitaxel • Herzuma (trastuzumab biosimilar) • Ontruzant (trastuzumab biosimilar) • Ogivri (trastuzumab biosimilar) • EG12014 (trastuzumab biosimilar) • EG-12 • GB221 (trastuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)
Phase 2/3
Institut für Klinische Krebsforschung IKF GmbH ...
Active, not recruiting
Last update posted :
08/26/2021
Initiation :
06/01/2016
Primary completion :
09/01/2021
Completion :
10/01/2021
HER-2 • SOCS1
|
HER-2 negative
|
5-fluorouracil • docetaxel • oxaliplatin • Cyramza (ramucirumab) • leucovorin calcium
Phase 1
GlaxoSmithKline
Active, not recruiting
Last update posted :
08/26/2021
Initiation :
06/23/2016
Primary completion :
06/20/2023
Completion :
06/20/2023
MSI • ICOS
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • gemcitabine • 5-fluorouracil • docetaxel • pemetrexed • Jemperli (dostarlimab) • bintrafusp alfa (M7824) • feladilimab (GSK3359609) • GSK3174998 • cobolimab (TSR-022)
Phase 2b
ImmunityBio, Inc.
Active, not recruiting
Last update posted :
08/25/2021
Initiation :
12/11/2018
Primary completion :
05/01/2023
Completion :
12/01/2023
BRAF • PD-L1 • ALK • MSI
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Anktiva (inbakicept) • PD-L1.t-haNK
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
08/25/2021
Initiation :
08/06/2021
Primary completion :
07/07/2023
Completion :
01/30/2024
PD-L1 • TIGIT
|
PD-L1 expression
|
Tecentriq (atezolizumab) • capecitabine • oxaliplatin • tiragolumab (MTIG7192A)
Phase 1
Chang Gung Memorial Hospital
Recruiting
Last update posted :
08/25/2021
Initiation :
04/09/2021
Primary completion :
06/30/2022
Completion :
06/30/2023
HER-2
|
HER-2 positive
Phase 3
Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting
Last update posted :
08/25/2021
Initiation :
03/07/2019
Primary completion :
02/01/2022
Completion :
03/01/2023
PD-L1
|
capecitabine • oxaliplatin • AiTan (rivoceranib) • AiRuiKa (camrelizumab)
Phase 2a
LianBio LLC
Recruiting
Last update posted :
08/25/2021
Initiation :
05/13/2020
Primary completion :
12/30/2022
Completion :
12/30/2023
FGFR2
|
FGFR2 mutation • FGFR2 amplification • FGFR2 fusion • FGFR3 fusion • FGFR1 fusion
|
Truseltiq (infigratinib)
Phase 2
Academic and Community Cancer Research United
Recruiting
Last update posted :
08/24/2021
Initiation :
11/02/2018
Primary completion :
11/07/2024
Completion :
07/01/2026
BRCA2 • BRCA1 • HRD • BRCA
|
BRCA1 mutation • BRCA2 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation
|
5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
Phase 2
Henan Cancer Hospital
Recruiting
Last update posted :
08/24/2021
Initiation :
07/30/2019
Primary completion :
05/30/2022
Completion :
07/30/2022
PD-L1 • MSI
|
docetaxel • oxaliplatin • Tyvyt (sintilimab)
Phase 3
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
08/24/2021
Initiation :
09/26/2018
Primary completion :
06/30/2022
Completion :
07/31/2023
HER-2 • CLDN18
|
HER-2 negative • CLDN18.2 expression
|
capecitabine • oxaliplatin • zolbetuximab (IMAB362)
Phase 1
Novartis Pharmaceuticals
Recruiting
Last update posted :
08/24/2021
Initiation :
05/22/2019
Primary completion :
10/09/2023
Completion :
04/01/2025
CRP
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • oxaliplatin • irinotecan • Cyramza (ramucirumab) • Cabometyx (cabozantinib tablet) • leucovorin calcium • gevokizumab (S 78989)
Phase 2
The First Affiliated Hospital of Zhengzhou Univ...
Not yet recruiting
Last update posted :
08/23/2021
Initiation :
12/01/2021
Primary completion :
05/31/2022
Completion :
12/31/2022
HER-2
|
PD-L1 expression • HER-2 positive
|
Herceptin (trastuzumab) • docetaxel • oxaliplatin • Baize’an (tislelizumab)
Phase 2
The First Affiliated Hospital of Zhengzhou Univ...
Not yet recruiting
Last update posted :
08/23/2021
Initiation :
01/01/2022
Primary completion :
05/31/2022
Completion :
12/31/2022
PD-L1
|
cisplatin • docetaxel • AiRuiKa (camrelizumab)
Phase 1
Cancer Research UK
Recruiting
Last update posted :
08/20/2021
Initiation :
06/21/2017
Primary completion :
01/31/2022
Completion :
01/31/2022
TP53
|
TP53 mutation
|
LY3143921
Phase 2
University of California, San Francisco
Recruiting
Last update posted :
08/19/2021
Initiation :
08/07/2020
Primary completion :
07/01/2022
Completion :
07/01/2025
PD-L1 • MSI • PD-1
Phase 1b/2
MacroGenics
Completed
Last update posted :
08/19/2021
Initiation :
01/01/2016
Primary completion :
01/01/2021
Completion :
01/01/2021
HER-2
|
HER-2 positive
|
Keytruda (pembrolizumab) • Margenza (margetuximab)
Phase 1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting
Last update posted :
08/18/2021
Initiation :
09/01/2021
Primary completion :
12/01/2023
Completion :
06/01/2024
CLDN18
|
CLDN18.2 expression
|
SYSA1801
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
08/18/2021
Initiation :
05/29/2019
Primary completion :
06/01/2024
Completion :
11/01/2025
HER-2 • PD-L1 • ER • PGR
|
HER-2 negative
|
Keytruda (pembrolizumab) • pavunalimab (XmAb22841)
Phase 1b
Athenex, Inc.
Active, not recruiting
Last update posted :
08/17/2021
Initiation :
12/08/2016
Primary completion :
03/27/2019
Completion :
12/31/2021
HER-2
|
HER-2 overexpression
|
Cyramza (ramucirumab) • Oraxol (oral paclitaxel/encequidar)
Phase 1
Seagen Inc.
Recruiting
Last update posted :
08/17/2021
Initiation :
06/08/2020
Primary completion :
11/30/2023
Completion :
11/30/2023
HER-2
|
HER-2 negative
|
SGN-B6A
Phase 2
SOLTI Breast Cancer Research Group
Recruiting
Last update posted :
08/16/2021
Initiation :
04/12/2021
Primary completion :
12/31/2023
Completion :
12/11/2024
PD-1
|
PD-1 expression
|
spartalizumab (PDR001)
Phase 2
Hoffmann-La Roche
Active, not recruiting
Last update posted :
08/13/2021
Initiation :
02/19/2018
Primary completion :
10/16/2021
Completion :
10/16/2021
CD8
|
Tecentriq (atezolizumab) • gemcitabine • vinorelbine tartrate • simlukafusp alfa (RG7461)
Phase 1
Craig L Slingluff, Jr
Recruiting
Last update posted :
08/13/2021
Initiation :
11/21/2019
Primary completion :
11/30/2022
Completion :
05/30/2023
PD-L1
|
Zyclara (imiquimod)
Phase N/A
The Christie NHS Foundation Trust
Recruiting
Last update posted :
08/13/2021
Initiation :
07/15/2021
Primary completion :
04/01/2025
Completion :
04/01/2026
IL6 • TNFA
Phase 1
Shattuck Labs, Inc.
Recruiting
Last update posted :
08/12/2021
Initiation :
03/26/2019
Primary completion :
02/02/2022
Completion :
04/05/2022
EGFR • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK fusion
|
TAK-252
Phase 2
Daiichi Sankyo, Inc.
Active, not recruiting
Last update posted :
08/12/2021
Initiation :
07/30/2019
Primary completion :
04/09/2021
Completion :
01/01/2022
HER-2
|
HER-2 positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 1
Adaptimmune
Recruiting
Last update posted :
08/12/2021
Initiation :
07/05/2017
Primary completion :
09/01/2032
Completion :
09/01/2035
HLA-A • MAGEA4
|
afamitresgene autoleucel (ADP-A2M4)
Phase 1/2
Gilead Sciences
Completed
Last update posted :
08/12/2021
Initiation :
12/17/2012
Primary completion :
03/01/2019
Completion :
08/13/2020
HER-2
|
HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy)
Phase 2
Zymeworks Inc.
Recruiting
Last update posted :
08/11/2021
Initiation :
08/29/2019
Primary completion :
03/31/2023
Completion :
04/30/2024
HER-2 • BRAF • KRAS • NRAS
|
HER-2 amplification • HER-2 expression
|
Avastin (bevacizumab) • cisplatin • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • zanidatamab (ZW25)
Phase 2
I-Mab Biopharma US Limited
Not yet recruiting
Last update posted :
08/11/2021
Initiation :
10/01/2021
Primary completion :
10/01/2024
Completion :
01/01/2025
HER-2 • PD-L1 • ER • PGR
|
PD-L1 expression • HER-2 negative • ER negative • PGR negative
|
Tecentriq (atezolizumab) • uliledlimab (TJD5)
Phase 1
University of Florida
Recruiting
Last update posted :
08/11/2021
Initiation :
01/10/2020
Primary completion :
01/01/2022
Completion :
10/01/2023
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase 2
Harry H Yoon
Recruiting
Last update posted :
08/10/2021
Initiation :
12/01/2020
Primary completion :
12/01/2022
Completion :
12/01/2023
PD-L1
|
Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab)
Phase 2
BeiGene
Recruiting
Last update posted :
08/09/2021
Initiation :
03/31/2021
Primary completion :
11/01/2023
Completion :
03/01/2024
PD-L1
|
Baize’an (tislelizumab) • ociperlimab (BGB-A1217)
Phase 1
MacroGenics
Active, not recruiting
Last update posted :
08/09/2021
Initiation :
08/18/2017
Primary completion :
05/01/2022
Completion :
07/01/2022
PD-L1 • PD-1 • LAG3
|
PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression
|
Margenza (margetuximab) • tebotelimab (MGD013)
Phase 1
Zymeworks Inc.
Recruiting
Last update posted :
08/06/2021
Initiation :
04/15/2019
Primary completion :
08/01/2023
Completion :
08/01/2025
HER-2
|
HER-2 expression • HER-2-H
|
ZW49
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
08/06/2021
Initiation :
10/05/2018
Primary completion :
06/01/2023
Completion :
03/20/2024
HER-2
|
HER-2 positive
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
Phase 2
University of Southampton
Not yet recruiting
Last update posted :
08/05/2021
Initiation :
08/19/2021
Primary completion :
11/01/2023
Completion :
11/01/2023
MGMT
|
Opdivo (nivolumab) • temozolomide
Phase 2
Academic and Community Cancer Research United
Recruiting
Last update posted :
08/05/2021
Initiation :
06/16/2021
Primary completion :
07/31/2023
Completion :
05/31/2026
HER-2
|
HER-2 positive
|
cisplatin • paclitaxel • Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • lexatumumab (ETR2-ST01)
Phase 1
Elpiscience Biopharma, Ltd.
Not yet recruiting
Last update posted :
08/05/2021
Initiation :
09/30/2021
Primary completion :
05/31/2024
Completion :
06/30/2025
EGFR • ALK • ROS1
|
EGFR mutation • ALK rearrangement
|
Tuoyi (toripalimab) • INBRX-106
Phase 1
Incyte Corporation
Not yet recruiting
Last update posted :
08/04/2021
Initiation :
08/21/2021
Primary completion :
05/21/2024
Completion :
05/21/2024
CD8 • CD73
|
retifanlimab (INCMGA0012) • INCA00186 • INCB106385
Phase N/A
Wuxi No. 4 People's Hospital
Not yet recruiting
Last update posted :
08/04/2021
Initiation :
08/01/2021
Primary completion :
08/31/2022
Completion :
08/31/2022
CLDN18
|
CLDN18.2 positive
Phase 2
Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting
Last update posted :
08/04/2021
Initiation :
09/01/2021
Primary completion :
08/01/2024
Completion :
08/01/2027
PD-L1
|
oxaliplatin • Tyvyt (sintilimab) • Teysuno (gimeracil/oteracil/tegafur)
Phase 1
Zymeworks Inc.
Recruiting
Last update posted :
08/04/2021
Initiation :
09/01/2016
Primary completion :
01/31/2022
Completion :
03/31/2022
EGFR • HER-2 • KRAS • ALK • ROS1
|
HER-2 positive • HER-2 overexpression • ALK-ROS1 fusion
|
paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • zanidatamab (ZW25)
Phase 2
Elevation Oncology
Recruiting
Last update posted :
08/03/2021
Initiation :
09/29/2020
Primary completion :
06/01/2022
Completion :
06/01/2023
NRG1
|
NRG1 fusion
|
seribantumab (MM-121)
Phase 3
Innovent Biologics (Suzhou) Co. Ltd.
Recruiting
Last update posted :
08/02/2021
Initiation :
12/24/2018
Primary completion :
07/30/2022
Completion :
07/30/2022
PD-L1
|
PD-L1 expression
|
cisplatin • paclitaxel • 5-fluorouracil • Tyvyt (sintilimab)
Phase 2
Merck Sharp & Dohme Corp.
Completed
Last update posted :
07/30/2021
Initiation :
02/03/2015
Primary completion :
07/23/2021
Completion :
07/23/2021
HER-2 • PD-L1
|
HER-2 negative
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • capecitabine
Phase 1/2
Suzhou Kintor Pharmaceutical Inc,
Not yet recruiting
Last update posted :
07/30/2021
Initiation :
08/01/2021
Primary completion :
09/01/2024
Completion :
09/01/2025
PD-L1
|
PD-L1 expression
|
KN046 • ascrinvacumab (GT90001)
Phase 2
Seagen Inc.
Recruiting
Last update posted :
07/29/2021
Initiation :
10/09/2019
Primary completion :
08/01/2022
Completion :
07/31/2023
BRAF • ALK • BRCA
|
HER-2 overexpression • BRAF mutation • BRCA mutation
|
ladiratuzumab vedotin (SGN-LIV1A)
Phase 1
Keymed Biosciences Co.Ltd
Recruiting
Last update posted :
07/29/2021
Initiation :
09/02/2020
Primary completion :
05/01/2022
Completion :
10/01/2022
CLDN18
|
CLDN18.2 positive
Phase 2
Tianjin Medical University Cancer Institute and...
Recruiting
Last update posted :
07/29/2021
Initiation :
06/21/2021
Primary completion :
06/21/2023
Completion :
06/21/2024
HER-2
|
HER-2 negative
|
oxaliplatin • Tyvyt (sintilimab) • Teysuno (gimeracil/oteracil/tegafur)
Phase 1
Novartis Pharmaceuticals
Recruiting
Last update posted :
07/27/2021
Initiation :
05/26/2017
Primary completion :
08/15/2023
Completion :
08/15/2023
KRAS
|
nazartinib (EGF816) • TNO-155
Phase 1
Novartis Pharmaceuticals
Recruiting
Last update posted :
07/27/2021
Initiation :
07/30/2019
Primary completion :
10/12/2023
Completion :
10/12/2023
EGFR • KRAS • ALK
|
KRAS G12C • KRAS G12
|
Kisqali (ribociclib) • spartalizumab (PDR001) • TNO-155
Phase 1/2
Dragonfly Therapeutics
Recruiting
Last update posted :
07/26/2021
Initiation :
07/10/2020
Primary completion :
09/01/2022
Completion :
12/01/2024
EGFR • HER-2 • BRAF • ALK • ER • PGR • ROS1
|
EGFR mutation • BRAF mutation • BRAF V600 • HER-2 negative • RET mutation • ER negative • PGR negative
|
Opdivo (nivolumab) • DF6002
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
07/23/2021
Initiation :
12/14/2020
Primary completion :
12/30/2024
Completion :
12/30/2038
HER-2
|
HER-2 positive
|
TT16
Phase 1
Inhibrx, Inc.
Recruiting
Last update posted :
07/22/2021
Initiation :
01/30/2019
Primary completion :
11/01/2022
Completion :
03/01/2023
EGFR • ALK
|
EGFR mutation • ALK rearrangement
|
Keytruda (pembrolizumab) • INBRX-105
Phase 1
I-Mab Biopharma Co. Ltd.
Recruiting
Last update posted :
07/22/2021
Initiation :
06/29/2021
Primary completion :
03/01/2024
Completion :
03/01/2024
CLDN18
|
CLDN18.2 positive
|
TJ-CD4B
Phase N/A
Buddhist Tzu Chi General Hospital
Recruiting
Last update posted :
07/21/2021
Initiation :
08/01/2020
Primary completion :
07/31/2023
Completion :
07/31/2027
PD-L1
Phase 2
Academisch Medisch Centrum - Universiteit van A...
Recruiting
Last update posted :
07/21/2021
Initiation :
01/27/2021
Primary completion :
05/01/2023
Completion :
01/01/2024
IL6
|
IL6 expression
|
carboplatin • paclitaxel • Actemra IV (tocilizumab)
Phase 2
AIO-Studien-gGmbH
Active, not recruiting
Last update posted :
07/21/2021
Initiation :
03/01/2018
Primary completion :
10/01/2021
Completion :
01/01/2022
HER-2 • TCRB
|
HER-2 positive
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • 5-fluorouracil • leucovorin calcium
Phase N/A
Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting
Last update posted :
07/21/2021
Initiation :
03/30/2017
Primary completion :
12/01/2021
Completion :
12/01/2021
TMB
Phase 2
NeoImmuneTech
Recruiting
Last update posted :
07/19/2021
Initiation :
01/21/2021
Primary completion :
08/29/2023
Completion :
01/18/2024
HER-2
|
PD-L1 expression
|
Opdivo (nivolumab) • Hyleukin-7 (efineptakin alfa)
Phase 1
University of Utah
Recruiting
Last update posted :
07/16/2021
Initiation :
03/17/2020
Primary completion :
01/30/2023
Completion :
01/30/2025
BRAF • KRAS • HRAS
|
BRAF mutation
|
ulixertinib (BVD-523) • hydroxychloroquine
Phase N/A
Hospices Civils de Lyon
Recruiting
Last update posted :
07/16/2021
Initiation :
12/04/2018
Primary completion :
01/04/2028
Completion :
01/04/2028
MUC16
|
BRAF V600E • EGFR mutation • BRAF V600 • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
|
cisplatin
Phase 1
Ludwig Institute for Cancer Research
Completed
Last update posted :
07/15/2021
Initiation :
09/03/2003
Primary completion :
09/05/2005
Completion :
06/06/2006
CD8 • CTAG1B • CTAG2
|
Promune (agatolimod)
Phase 1/2
Tarveda Therapeutics
Recruiting
Last update posted :
07/14/2021
Initiation :
08/29/2017
Primary completion :
12/01/2021
Completion :
06/01/2022
HSP90AA1
|
5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • PEN-866
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
07/14/2021
Initiation :
08/10/2020
Primary completion :
08/10/2022
Completion :
08/10/2022
HER-2
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab)
Phase N/A
Wake Forest University Health Sciences
Completed
Last update posted :
07/13/2021
Initiation :
08/01/2016
Primary completion :
01/01/2020
Completion :
01/01/2020
IL6 • TNFA
Phase 2
Peking University
Not yet recruiting
Last update posted :
07/13/2021
Initiation :
07/01/2021
Primary completion :
10/01/2022
Completion :
05/01/2023
EGFR
|
EGFR amplification
|
Gilotrif (afatinib) • Tuoyi (toripalimab)
Phase 1b
ADC Therapeutics S.A.
Recruiting
Last update posted :
07/13/2021
Initiation :
11/09/2018
Primary completion :
11/15/2022
Completion :
11/15/2023
MSI
|
Keytruda (pembrolizumab) • camidanlumab tesirine (ADCT-301)
Phase 1b/2
Seagen Inc.
Recruiting
Last update posted :
07/13/2021
Initiation :
09/15/2020
Primary completion :
07/31/2021
Completion :
11/30/2022
HER-2
|
HER-2 amplification • HER-2 overexpression
|
Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium
Phase 
Fundación Sociedad Española de Oncologia Médica
Recruiting
Last update posted :
07/12/2021
Initiation :
04/27/2020
Primary completion :
12/01/2034
Completion :
12/01/2035
HER-2
|
HER-2 overexpression
Phase 1/2
OBI Pharma, Inc
Active, not recruiting
Last update posted :
07/09/2021
Initiation :
12/10/2019
Primary completion :
11/09/2023
Completion :
12/09/2023
CD4
|
OBI-999
Phase 2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
07/09/2021
Initiation :
02/01/2011
Primary completion :
12/01/2021
Completion :
01/01/2022
HER-2
|
HER-2 positive
|
Herceptin (trastuzumab) • Avastin (bevacizumab) • capecitabine • oxaliplatin
Phase 3
Sunshine Lake Pharma Co., Ltd.
Recruiting
Last update posted :
07/08/2021
Initiation :
01/21/2021
Primary completion :
08/01/2022
Completion :
11/01/2022
EGFR
|
EGFR expression • EGFR overexpression
|
irinotecan • Teysuno (gimeracil/oteracil/tegafur) • larotinib (Z650)
Phase 2
The First Affiliated Hospital of Zhengzhou Univ...
Not yet recruiting
Last update posted :
07/07/2021
Initiation :
09/01/2021
Primary completion :
12/01/2022
Completion :
09/01/2023
EGFR
|
AiRuiKa (camrelizumab) • TheraCIM (nimotuzumab)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/05/2021
Initiation :
08/12/2015
Primary completion :
03/09/2019
HER-2
|
HER-2 amplification
|
Kadcyla (ado-trastuzumab emtansine)
Phase 3
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting
Last update posted :
07/05/2021
Initiation :
09/15/2021
Primary completion :
03/15/2025
Completion :
06/30/2025
HER-2
|
PD-L1 expression • HER-2 amplification • HER-2 overexpression
|
5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • SHR-1701
Phase 3
Merck Sharp & Dohme Corp.
Completed
Last update posted :
07/02/2021
Initiation :
05/11/2015
Primary completion :
10/26/2017
Completion :
06/10/2021
HER-2 • PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • paclitaxel
Phase 1
Symphogen A/S
Recruiting
Last update posted :
07/02/2021
Initiation :
11/19/2020
Primary completion :
03/01/2024
Completion :
03/01/2024
MSI
|
MSI-H/dMMR
|
Sym021 • Sym024
Phase 2
Pamela L. Kunz
Completed
Last update posted :
07/01/2021
Initiation :
02/01/2009
Primary completion :
12/31/2017
Completion :
12/31/2017
VEGFA
|
Avastin (bevacizumab) • carboplatin • capecitabine
Phase 2
Henan Cancer Hospital
Recruiting
Last update posted :
07/01/2021
Initiation :
04/28/2021
Primary completion :
06/03/2022
Completion :
08/03/2023
HER-2 • PD-L1
|
HER-2 positive • HER-2 negative
|
AiTan (rivoceranib) • AiRuiKa (camrelizumab)
Phase 1
Daiichi Sankyo Co., Ltd.
Recruiting
Last update posted :
06/29/2021
Initiation :
01/31/2018
Primary completion :
01/01/2024
Completion :
01/01/2024
EGFR • HER-2 • ER • PGR • ERBB3 • TROP2
|
HR positive • HER-2 negative • HER-2 expression
|
datopotamab deruxtecan (DS-1062a)
Phase 2
Weill Medical College of Cornell University
Recruiting
Last update posted :
06/25/2021
Initiation :
05/09/2019
Primary completion :
12/31/2021
Completion :
12/31/2022
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • telomelysin (OBP-301)
Phase 1
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Co...
Active, not recruiting
Last update posted :
06/24/2021
Initiation :
04/02/2018
Primary completion :
09/14/2018
Completion :
09/01/2021
HER-2
|
HER-2 positive • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 2
Asan Medical Center
Recruiting
Last update posted :
06/24/2021
Initiation :
03/12/2020
Primary completion :
12/31/2021
Completion :
09/30/2022
HER-2
|
HER-2 negative
|
cisplatin • capecitabine • Ontruzant (trastuzumab biosimilar)
Phase 1
Daiichi Sankyo Co., Ltd.
Active, not recruiting
Last update posted :
06/23/2021
Initiation :
09/01/2015
Primary completion :
02/01/2019
Completion :
09/30/2021
HER-2
|
HER-2 positive • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 2
Federation Francophone de Cancerologie Digestive
Active, not recruiting
Last update posted :
06/22/2021
Initiation :
07/17/2019
Primary completion :
11/15/2023
Completion :
07/31/2024
MSI
|
cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • irinotecan • tremelimumab (CP-675206) • leucovorin calcium
Phase 2
Nanfang Hospital of Southern Medical University
Recruiting
Last update posted :
06/21/2021
Initiation :
03/12/2021
Primary completion :
12/30/2021
Completion :
12/30/2024
PD-L1 • MSI
|
PD-L1 expression • MSI-H/dMMR
|
capecitabine • oxaliplatin • Tuoyi (toripalimab) • Teysuno (gimeracil/oteracil/tegafur)
Phase N/A
Rutgers, The State University of New Jersey
Active, not recruiting
Last update posted :
06/17/2021
Initiation :
04/29/2021
Primary completion :
11/01/2024
Completion :
11/01/2024
MUC16 • Cancer antigen 19-9
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
06/16/2021
Initiation :
11/08/2018
Primary completion :
11/29/2024
Completion :
11/29/2024
HER-2 • PD-L1 • MSI
|
PD-L1 expression • HER-2 negative
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin
Phase 1b
BeiGene
Recruiting
Last update posted :
06/16/2021
Initiation :
06/28/2017
Primary completion :
03/30/2023
Completion :
06/30/2023
AR • HRD • BRCA
|
HRD • BRCA mutation
|
temozolomide • Partruvix (pamiparib)
Phase 1b/2
City of Hope Medical Center
Suspended
Last update posted :
06/15/2021
Initiation :
04/19/2019
Primary completion :
02/19/2022
Completion :
02/19/2022
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • citoplurikin (IRX-2) • cyclophosphamide intravenous
Phase 
Centre Hospitalier Universitaire de Besancon
Completed
Last update posted :
06/10/2021
Initiation :
04/01/2021
Primary completion :
05/31/2021
Completion :
05/31/2021
HER-2
|
paclitaxel • docetaxel
Phase 1
Apollomics (Australia) Pty. Ltd.
Active, not recruiting
Last update posted :
06/09/2021
Initiation :
03/27/2017
Primary completion :
12/01/2021
Completion :
06/01/2022
MSI
|
MSI-H/dMMR
|
geptanolimab (GB226)
Phase 2
NYU Langone Health
Recruiting
Last update posted :
06/08/2021
Initiation :
10/24/2017
Primary completion :
12/15/2021
Completion :
12/15/2022
HER-2
|
HER-2 positive
|
Keytruda (pembrolizumab) • lenvatinib
Phase 2
University of Chicago
Recruiting
Last update posted :
06/08/2021
Initiation :
10/11/2019
Primary completion :
02/01/2023
Completion :
02/01/2025
HER-2
|
HER-2 negative
|
Keytruda (pembrolizumab)
Phase 1b
Atreca, Inc.
Recruiting
Last update posted :
06/02/2021
Initiation :
02/11/2020
Primary completion :
12/01/2024
Completion :
03/01/2025
BRAF • MSI
|
MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab) • ATRC-101
Phase 2
Tianjin Medical University Cancer Institute and...
Recruiting
Last update posted :
05/31/2021
Initiation :
05/01/2021
Primary completion :
08/01/2023
Completion :
08/01/2028
PD-L1
|
5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 3
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
05/31/2021
Initiation :
10/12/2016
Primary completion :
05/27/2020
Completion :
10/06/2022
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
Phase 2a
Janssen Research & Development, LLC
Active, not recruiting
Last update posted :
05/27/2021
Initiation :
07/08/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
FGFR
|
FGFR mutation
|
Balversa (erdafitinib)
Phase N/A
Massive Bio, Inc.
Recruiting
Last update posted :
05/25/2021
Initiation :
01/01/2018
Primary completion :
06/01/2022
Completion :
12/01/2022
EGFR • HER-2 • BRAF • PD-L1 • KRAS • ALK • ER • TP53 • FLT3 • ABL1 • TMB • NRAS • BRCA2 • BRCA1 • PTEN • FGFR2 • NTRK1 • NTRK3 • ROS1 • BCL2 • NTRK2 • IDH1 • HRAS • NPM1 • IDH2 • STK11 • DNMT3A • PDGFRA • JAK2 • ERBB3 • RB1 • NF1 • AKT1 • POLE • CCND1 • MCL1 • PDGFRB • PBRM1 • BCL6 • KDR • PD-1 • PTCH1 • BAP1 • VEGFA • MAP2K2 • MDM2 • MSH6 • FBXW7 • MSH2 • ATRX • CDK4 • CTNNB1 • FGFR4 • TSC2 • WT1 • TSC1 • CLDN18 • ERBB4 • JAK1 • PD-L2 • RAF1 • MDM4 • POLD1 • CHEK2 • FANCA • CEBPA • JAK3 • RICTOR • AURKA • MSH3 • TGFBR2 • CDK6 • CHEK1 • GATA6 • AKT2 • BRCA • CCND3 • MAP3K1 • MYCL • CCND2 • CSF1R • GNAS • HDAC1 • PARP1 • PRDM1 • ZNF217 • CDKN1A • ERCC4 • GATA3 • PARP2 • SDHA
|
FGFR2 fusion • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
Phase 1/2
Millennium Pharmaceuticals, Inc.
Recruiting
Last update posted :
05/25/2021
Initiation :
06/16/2016
Primary completion :
03/30/2022
Completion :
03/13/2023
EGFR • HER-2
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
|
carboplatin • pemetrexed • Exkivity (mobocertinib)
Phase 2
University Hospital, Essen
Recruiting
Last update posted :
05/21/2021
Initiation :
09/26/2019
Primary completion :
04/01/2023
Completion :
06/01/2025
LAG3
|
LAG3 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • docetaxel • oxaliplatin • leucovorin calcium • relatlimab (BMS-986016)
Phase N/A
Guangzhou University of Traditional Chinese Med...
Completed
Last update posted :
05/20/2021
Initiation :
01/04/2019
Primary completion :
04/27/2020
Completion :
04/27/2020
CD8 • IL6 • IFNG • TNFA • IL2 • CXCL12 • FGF • IL10 • IL17A • IL18 • IFNA1 • IL1B • IL22 • BDNF • IL21
Phase 2
Zhou Fuxiang
Recruiting
Last update posted :
05/17/2021
Initiation :
05/14/2021
Primary completion :
08/01/2024
Completion :
08/01/2025
HER-2
|
HER-2 negative
|
docetaxel • AiTan (rivoceranib) • AiRuiKa (camrelizumab)
Phase N/A
Zhejiang Cancer Hospital
Not yet recruiting
Last update posted :
05/17/2021
Initiation :
07/31/2021
Primary completion :
07/31/2023
Completion :
07/31/2025
HER-2
|
paclitaxel • AiRuiKa (camrelizumab) • Teysuno (gimeracil/oteracil/tegafur)
Phase 2
National Cancer Center, Korea
Recruiting
Last update posted :
05/14/2021
Initiation :
09/01/2019
Primary completion :
12/31/2022
Completion :
12/31/2023
EGFR
|
EGFR amplification
|
paclitaxel • rogaratinib (BAY1163877) • GC-1118A
Phase 1b
University of Michigan
Recruiting
Last update posted :
05/13/2021
Initiation :
05/09/2019
Primary completion :
12/01/2021
Completion :
12/01/2021
EGFR • HER-2
Phase 1
Adaptimmune
Recruiting
Last update posted :
05/13/2021
Initiation :
08/20/2019
Primary completion :
04/30/2022
Completion :
04/30/2037
HLA-A • MAGEA4
|
MAGEA4 expression
|
ADP-A2M4CD8 • afamitresgene autoleucel (ADP-A2M4)
Phase 1/2
NKGen Biotech, Inc.
Withdrawn
Last update posted :
05/12/2021
Initiation :
03/01/2021
Primary completion :
08/01/2022
Completion :
02/01/2023
EGFR • HER-2
|
EGFR positive
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • SNK01
Phase 2
Autumn McRee, MD
Active, not recruiting
Last update posted :
05/12/2021
Initiation :
01/24/2019
Primary completion :
09/11/2020
Completion :
01/01/2022
HER-2
|
HER-2 amplification
|
Herceptin (trastuzumab) • 5-fluorouracil • Bavencio (avelumab) • oxaliplatin • leucovorin calcium
Phase 1
Athenex, Inc.
Recruiting
Last update posted :
05/11/2021
Initiation :
10/25/2018
Primary completion :
03/30/2023
Completion :
06/30/2023
EGFR • ALK
|
ALK translocation
|
Keytruda (pembrolizumab) • Oraxol (oral paclitaxel/encequidar)
Phase 2
University of Wisconsin, Madison
Recruiting
Last update posted :
05/11/2021
Initiation :
07/13/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive • HER-2 negative
|
Herceptin (trastuzumab) • 5-fluorouracil • Onivyde (nanoliposomal irinotecan)
Phase 3
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
05/07/2021
Initiation :
06/29/2017
Primary completion :
01/18/2021
Completion :
08/16/2024
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • 5-fluorouracil
Phase 3
Australasian Gastro-Intestinal Trials Group
Recruiting
Last update posted :
05/07/2021
Initiation :
11/01/2016
Primary completion :
06/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive
|
Stivarga (regorafenib)
Phase 1
Peking University
Recruiting
Last update posted :
05/07/2021
Initiation :
03/26/2019
Primary completion :
03/20/2022
Completion :
03/20/2022
CLDN18
|
CT041
Phase 3
Ottawa Hospital Research Institute
Not yet recruiting
Last update posted :
05/04/2021
Initiation :
07/01/2021
Primary completion :
07/01/2023
Completion :
07/01/2024
IFNG • CRP
Phase 2/3
MacroGenics
Recruiting
Last update posted :
05/03/2021
Initiation :
09/30/2019
Primary completion :
05/01/2024
Completion :
05/01/2026
PD-L1 • MSI
|
PD-L1 expression • HER-2 positive
|
Herceptin (trastuzumab) • capecitabine • oxaliplatin • Margenza (margetuximab) • tebotelimab (MGD013) • retifanlimab (INCMGA0012)
Phase 2
Five Prime Therapeutics, Inc.
Active, not recruiting
Last update posted :
05/03/2021
Initiation :
09/14/2018
Primary completion :
09/23/2020
Completion :
05/31/2022
FGFR2
|
FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression
|
bemarituzumab (FPA-144)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
04/29/2021
Initiation :
07/10/2018
Primary completion :
02/28/2022
Completion :
02/28/2023
HER-2 • ER • PGR • MSI
|
MSI-H/dMMR • HER-2 negative
|
vudalimab (XmAb717)
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
04/28/2021
Initiation :
11/08/2018
Primary completion :
09/28/2024
Completion :
09/28/2024
HER-2 • PD-L1 • MSI
|
PD-L1 expression • HER-2 negative
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin
Phase N/A
University of Cambridge
Completed
Last update posted :
04/28/2021
Initiation :
01/01/2018
Primary completion :
12/31/2020
Completion :
12/31/2020
CCNA2
Phase 1
Shanghai Junshi Bioscience Co., Ltd.
Recruiting
Last update posted :
04/27/2021
Initiation :
03/14/2018
Primary completion :
08/01/2022
Completion :
08/01/2023
MSI
|
MSI-H/dMMR
|
Tuoyi (toripalimab)
Phase 3
Zhejiang University
Withdrawn
Last update posted :
04/27/2021
Initiation :
03/01/2016
Primary completion :
10/01/2018
Completion :
12/01/2018
BRAF
|
aspirin
Phase 3
RemeGen
Recruiting
Last update posted :
04/27/2021
Initiation :
03/24/2021
Primary completion :
07/01/2022
Completion :
12/31/2024
HER-2
|
HER-2 overexpression
|
paclitaxel • irinotecan • Aidixi (disitamab vedotin)
Phase 1
Eisai Co., Ltd.
Recruiting
Last update posted :
04/23/2021
Initiation :
02/05/2018
Primary completion :
03/01/2023
Completion :
03/01/2023
HER-2
|
HER-2 negative
|
E7130
Phase N/A
Johannes Laengle, MD, PhD
Active, not recruiting
Last update posted :
04/23/2021
Initiation :
02/01/2021
Primary completion :
12/01/2021
Completion :
06/01/2022
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • paclitaxel • capecitabine
Phase N/A
Yonsei University
Active, not recruiting
Last update posted :
04/22/2021
Initiation :
01/01/2016
Primary completion :
12/01/2021
Completion :
06/01/2022
PD-L1
|
Opdivo (nivolumab) • GSK2636771
Phase 2
Yonsei University
Active, not recruiting
Last update posted :
04/22/2021
Initiation :
07/01/2016
Primary completion :
12/01/2021
Completion :
12/01/2022
EGFR • HER-2
|
HER-2 positive • EGFR expression
|
Gilotrif (afatinib) • paclitaxel
Phase 2
Institut für Klinische Krebsforschung IKF GmbH ...
Active, not recruiting
Last update posted :
04/19/2021
Initiation :
09/14/2018
Primary completion :
10/15/2025
Completion :
10/15/2025
PD-L1 • MSI • CD8
|
CD8 positive
|
Tecentriq (atezolizumab) • 5-fluorouracil • docetaxel • oxaliplatin • leucovorin calcium
Phase 2
University of Kansas Medical Center
Recruiting
Last update posted :
04/19/2021
Initiation :
06/27/2018
Primary completion :
04/30/2022
Completion :
04/30/2023
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
Phase 1
BeiGene
Recruiting
Last update posted :
04/15/2021
Initiation :
08/26/2019
Primary completion :
07/01/2023
Completion :
08/01/2023
PD-L1
|
PD-L1 expression
|
cisplatin • carboplatin • 5-fluorouracil • capecitabine • etoposide IV • oxaliplatin • Abraxane (albumin-bound paclitaxel) • pemetrexed • Baize’an (tislelizumab) • ociperlimab (BGB-A1217)
Phase 1
Elpiscience Biopharma, Ltd.
Recruiting
Last update posted :
04/14/2021
Initiation :
03/26/2021
Primary completion :
09/30/2022
Completion :
12/31/2022
EGFR • PD-L1 • ALK • ROS1
|
EGFR mutation • ALK rearrangement
|
INBRX-106
Phase 2
China Medical University, China
Recruiting
Last update posted :
04/14/2021
Initiation :
10/01/2019
Primary completion :
09/30/2021
Completion :
09/30/2021
PD-L1
|
PD-L1 expression
|
capecitabine • oxaliplatin • Tyvyt (sintilimab)
Phase 1
Molecular Templates, Inc.
Recruiting
Last update posted :
04/13/2021
Initiation :
11/12/2019
Primary completion :
05/01/2023
Completion :
05/01/2025
HER-2
|
HER-2 positive
|
MT-5111
Phase 2
Shadia Jalal, MD
Recruiting
Last update posted :
04/13/2021
Initiation :
07/09/2019
Primary completion :
05/01/2021
Completion :
05/01/2022
BRCA2 • BRCA1 • ARID1A • CDK12 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • RAD54L • BARD1 • NBN • GEN1
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Active, not recruiting
Last update posted :
04/09/2021
Initiation :
07/11/2017
Primary completion :
02/01/2022
Completion :
02/01/2024
PD-1
|
Opdivo (nivolumab) • carboplatin • paclitaxel • relatlimab (BMS-986016) • nivolumab/relatlimab (BMS-986213)
Phase 1
Bayer
Completed
Last update posted :
04/09/2021
Initiation :
06/19/2018
Primary completion :
11/16/2020
Completion :
02/22/2021
IL2 • CEACAM5 • CEACAM6
|
tinurilimab (BAY1834942)
Phase 2
University of Chicago
Completed
Last update posted :
04/08/2021
Initiation :
01/20/2015
Primary completion :
02/01/2020
Completion :
08/20/2020
EGFR • HER-2 • PD-1
|
HER-2 amplification
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • Cyramza (ramucirumab) • bemarituzumab (FPA-144) • depatuxizumab (ABT-806)
Phase 1/2
Seagen Inc.
Completed
Last update posted :
04/08/2021
Initiation :
11/30/2015
Primary completion :
12/13/2017
Completion :
12/13/2017
MUC16
|
Tivdak (tisotumab vedotin-tftv)
Phase 1/2
Treadwell Therapeutics, Inc
Recruiting
Last update posted :
04/07/2021
Initiation :
08/31/2020
Primary completion :
12/01/2021
Completion :
06/01/2024
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • CFI-402411
Phase 1b/2
Mayo Clinic
Suspended
Last update posted :
04/07/2021
Initiation :
06/24/2016
Primary completion :
04/01/2022
Completion :
04/01/2022
ALB
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • oxaliplatin • leucovorin calcium • fluorouracil topical
Phase 1
Eli Lilly and Company
Active, not recruiting
Last update posted :
04/06/2021
Initiation :
07/29/2015
Primary completion :
08/31/2018
Completion :
10/30/2021
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Cyramza (ramucirumab)
Phase 1
Jonsson Comprehensive Cancer Center
Recruiting
Last update posted :
04/05/2021
Initiation :
11/05/2019
Primary completion :
06/01/2030
Completion :
10/17/2031
FOLH1 • FAP
|
FOLH1 expression
|
FAPI-46
Phase 1/2
BeiGene
Recruiting
Last update posted :
04/02/2021
Initiation :
05/25/2020
Primary completion :
03/26/2025
Completion :
04/26/2025
PD-L1 • MSI
|
MSI-H/dMMR
|
Baize’an (tislelizumab) • Brukinsa (zanubrutinib) • BGB-10188
Phase 2
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting
Last update posted :
04/01/2021
Initiation :
08/01/2021
Primary completion :
08/01/2024
Completion :
12/01/2024
HER-2
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
DP303c
Phase 1a/1b
BeiGene
Completed
Last update posted :
04/01/2021
Initiation :
06/02/2015
Primary completion :
08/12/2020
Completion :
08/12/2020
EGFR • PD-L1 • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK rearrangement
|
Baize’an (tislelizumab)
Phase N/A
Hospital Universitario Virgen de la Arrixaca
Not yet recruiting
Last update posted :
04/01/2021
Initiation :
09/01/2021
Primary completion :
12/01/2023
Completion :
12/01/2025
KIT • CD34
Phase 1
Zai Lab (Shanghai) Co., Ltd.
Recruiting
Last update posted :
04/01/2021
Initiation :
02/03/2020
Primary completion :
12/30/2024
Completion :
12/30/2024
HER-2 • ER • PGR • FGFR2 • IDH1 • HRD • LAG3
|
PD-L1 expression • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • LAG3 expression • PGR expression
|
Zejula (niraparib) • tebotelimab (MGD013)
Phase 1
University Health Network, Toronto
Recruiting
Last update posted :
04/01/2021
Initiation :
09/01/2016
Primary completion :
09/01/2021
Completion :
09/01/2021
CTAG1B • HLA-A
|
CTAG1B expression
|
fludarabine IV • cyclophosphamide intravenous • mipetresgene autoleucel (TBI-1301)
Phase 2
National Health Research Institutes, Taiwan
Active, not recruiting
Last update posted :
03/30/2021
Initiation :
12/24/2018
Primary completion :
12/31/2021
Completion :
12/31/2022
UGT1A1 • UGT1A9
|
UGT1A1*1*1
|
5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
Phase 2
Hospices Civils de Lyon
Recruiting
Last update posted :
03/29/2021
Initiation :
03/19/2021
Primary completion :
10/26/2023
Completion :
10/26/2023
HER-2
|
HER-2 overexpression
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (GDC-0068)
Phase 2
AIO-Studien-gGmbH
Completed
Last update posted :
03/26/2021
Initiation :
09/01/2014
Primary completion :
10/08/2020
Completion :
10/08/2020
HER-2
|
HER-2 negative
|
cisplatin • 5-fluorouracil • docetaxel • capecitabine • oxaliplatin • epirubicin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)
Phase 2
Genentech, Inc.
Completed
Last update posted :
03/23/2021
Initiation :
08/31/2013
Primary completion :
06/03/2015
Completion :
01/26/2021
PTEN
|
PTEN loss
|
5-fluorouracil • oxaliplatin • ipatasertib (GDC-0068) • leucovorin calcium
Phase 2
AHS Cancer Control Alberta
Not yet recruiting
Last update posted :
03/22/2021
Initiation :
08/31/2021
Primary completion :
08/31/2023
Completion :
08/31/2027
HER-2
|
HER-2 negative
|
oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil)
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
03/19/2021
Initiation :
03/01/2012
Primary completion :
02/01/2022
Completion :
02/01/2022
HER-2
|
HER-2 positive • HER-2 amplification • HER-2 overexpression
|
Herceptin (trastuzumab) • Gilotrif (afatinib) • paclitaxel
Phase N/A
Samsung Medical Center
Recruiting
Last update posted :
03/19/2021
Initiation :
11/01/2013
Primary completion :
11/01/2022
Completion :
12/01/2023
EGFR • BRAF • ALK
|
EGFR mutation • BRAF mutation • EGFR T790M • ALK mutation
Phase 1/2
Sunshine Lake Pharma Co., Ltd.
Active, not recruiting
Last update posted :
03/18/2021
Initiation :
08/18/2017
Primary completion :
04/30/2021
Completion :
06/30/2021
EGFR
|
EGFR overexpression
|
larotinib (Z650)
Phase 2
Peking University
Recruiting
Last update posted :
03/18/2021
Initiation :
04/01/2021
Primary completion :
03/01/2023
Completion :
03/01/2024
PD-L1
|
PD-L1 expression
|
cisplatin • paclitaxel • Tuoyi (toripalimab)
Phase 1
VM Oncology, LLC
Recruiting
Last update posted :
03/15/2021
Initiation :
06/08/2018
Primary completion :
06/01/2022
Completion :
12/01/2022
NTRK1
|
NTRK1 fusion • NTRK1 mutation • NTRK expression
|
VMD-928
Phase 3
Innovent Biologics (Suzhou) Co. Ltd.
Recruiting
Last update posted :
03/12/2021
Initiation :
03/10/2021
Primary completion :
12/31/2023
Completion :
03/31/2025
HER-2 • PD-L1
|
PD-L1 expression • HER-2 negative • PD-L1 negative
|
cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Tyvyt (sintilimab) • Cyramza (ramucirumab)
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
07/31/2015
Primary completion :
03/26/2019
Completion :
06/06/2022
HER-2 • PD-L1
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • capecitabine
Phase N/A
City of Hope Medical Center
Active, not recruiting
Last update posted :
03/09/2021
Initiation :
11/19/2014
Primary completion :
12/30/2021
Completion :
12/30/2021
HER-2
|
HER-2 negative
|
Herceptin (trastuzumab)
Phase 2a
Leap Therapeutics, Inc.
Recruiting
Last update posted :
03/09/2021
Initiation :
07/29/2020
Primary completion :
12/01/2021
Completion :
05/01/2022
DKK1
|
capecitabine • oxaliplatin • Baize’an (tislelizumab) • DKN-01
Phase 1/2
Canadian Cancer Trials Group
Active, not recruiting
Last update posted :
03/09/2021
Initiation :
10/31/2014
Primary completion :
09/19/2019
Completion :
12/31/2021
PD-L1 • MAGEA3
|
EGFR mutation • ALK mutation
Phase 1
Astellas Pharma Inc
Completed
Last update posted :
03/05/2021
Initiation :
05/17/2018
Primary completion :
03/03/2020
Completion :
03/03/2020
CLDN18
|
zolbetuximab (IMAB362)
Phase 1/2
ImmuneSensor Therapeutics Inc.
Recruiting
Last update posted :
03/05/2021
Initiation :
09/23/2019
Primary completion :
02/16/2023
Completion :
02/16/2023
PD-L1
|
HR negative
|
IMSA101
Phase 3
ECOG-ACRIN Cancer Research Group
Recruiting
Last update posted :
03/05/2021
Initiation :
02/06/2020
Primary completion :
12/31/2023
Completion :
12/31/2023
HER-2 • CD4
|
HER-2 negative
|
capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
Phase 2
Taizhou Hanzhong biomedical co. LTD
Active, not recruiting
Last update posted :
03/04/2021
Initiation :
09/30/2018
Primary completion :
12/30/2019
Completion :
03/30/2021
MSI
|
MSI-H/dMMR
|
pucotenlimab (HX008)
Phase 2
Peking University
Recruiting
Last update posted :
03/04/2021
Initiation :
03/01/2021
Primary completion :
01/01/2023
Completion :
05/01/2023
MSI
|
MSI-H/dMMR
|
Focus V (anlotinib) • Baize’an (tislelizumab)
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
Last update posted :
03/03/2021
Initiation :
03/01/2021
Primary completion :
03/01/2024
Completion :
03/01/2027
HER-2 • BRCA2 • BRCA1 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • RAD54L • ARID2 • BARD1 • NBN
|
HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • PBRM1 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • NBN mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 1/2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
03/02/2021
Initiation :
11/01/2016
Primary completion :
11/01/2023
Completion :
11/01/2023
HER-2
|
HER-2 positive
|
carboplatin • paclitaxel • Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase 1/2
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Active, not recruiting
Last update posted :
03/01/2021
Initiation :
01/28/2021
Primary completion :
09/01/2023
Completion :
11/01/2023
CLDN18
|
CLDN18.2 positive
|
ASKB589
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/25/2021
Initiation :
01/20/2021
Primary completion :
07/01/2022
Completion :
07/01/2022
PDGFRA
|
PDGFRA mutation
|
Ayvakit (avapritinib)
Phase 2
Daiichi Sankyo Co., Ltd.
Completed
Last update posted :
02/23/2021
Initiation :
10/12/2017
Primary completion :
11/08/2019
Completion :
12/11/2020
HER-2
|
HER-2 expression
|
paclitaxel • irinotecan • Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 3
Jiangsu HengRui Medicine Co., Ltd.
Recruiting
Last update posted :
02/23/2021
Initiation :
09/21/2020
Primary completion :
04/01/2022
Completion :
09/01/2022
HER-2 • PD-L1
|
PD-L1 expression
|
paclitaxel • AiTan (rivoceranib) • AiRuiKa (camrelizumab) • irinotecan
Phase 2
Hunan Cancer Hospital
Recruiting
Last update posted :
02/23/2021
Initiation :
03/01/2021
Primary completion :
03/01/2023
Completion :
03/01/2023
PD-L1
|
carboplatin • paclitaxel • Abraxane (albumin-bound paclitaxel) • AiRuiKa (camrelizumab)
Phase 3
University College, London
Recruiting
Last update posted :
02/19/2021
Initiation :
10/01/2015
Primary completion :
10/01/2026
Completion :
10/01/2026
HER-2 • ER
|
HER-2 positive • HR positive • ER positive • HER-2 negative • ER negative • HR negative
|
aspirin
Phase 1/2
Incyte Corporation
Completed
Last update posted :
02/16/2021
Initiation :
07/17/2014
Primary completion :
11/26/2018
Completion :
11/06/2020
HER-2 • BRAF • ALK • ER • PGR • MSI
|
BRAF V600E • EGFR mutation • MSI-H/dMMR • BRAF V600 • HER-2 negative • ALK positive • ALK fusion
|
Keytruda (pembrolizumab) • epacadostat (INCB024360)
Phase 1
Taizhou HoudeAoke Biomedical Co., Ltd.
Recruiting
Last update posted :
02/16/2021
Initiation :
06/17/2019
Primary completion :
06/30/2021
Completion :
06/30/2022
PD-L1
|
PD-L1 expression
|
cisplatin • 5-fluorouracil • LP002
Phase N/A
IRCCS Policlinico S. Matteo
Recruiting
Last update posted :
02/12/2021
Initiation :
04/14/2020
Primary completion :
10/30/2023
Completion :
10/30/2023
HER-2
Phase 2
City of Hope Medical Center
Active, not recruiting
Last update posted :
02/11/2021
Initiation :
10/05/2016
Primary completion :
01/20/2022
Completion :
01/20/2022
HER-2 • PD-L2
|
HER-2 overexpression
|
Keytruda (pembrolizumab)
Phase 1a/1b
Coherent Biopharma (Suzhou) Co., Ltd.
Recruiting
Last update posted :
02/09/2021
Initiation :
03/06/2019
Primary completion :
09/01/2022
Completion :
12/01/2022
ALB
Phase N/A
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
02/09/2021
Initiation :
12/01/2005
Primary completion :
12/01/2021
Completion :
12/01/2021
CDH1
|
CDH1 mutation
Phase 3
CStone Pharmaceuticals
Recruiting
Last update posted :
02/08/2021
Initiation :
03/28/2019
Primary completion :
04/30/2022
Completion :
12/31/2023
PD-L1
|
PD-L1 expression
|
capecitabine • oxaliplatin • sugemalimab (CS1001)
Phase 1a
Five Prime Therapeutics, Inc.
Active, not recruiting
Last update posted :
02/04/2021
Initiation :
11/30/2017
Primary completion :
07/01/2022
Completion :
07/01/2024
FGFR
|
bemarituzumab (FPA-144)
Phase N/A
Centre of Postgraduate Medical Education
Recruiting
Last update posted :
02/04/2021
Initiation :
01/01/2021
Primary completion :
11/01/2023
Completion :
11/01/2024
TP53 • NOTCH1 • KMT2D • NFE2L2 • MLL2 • CHN1
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
02/04/2021
Initiation :
09/01/2019
Primary completion :
05/01/2021
Completion :
12/01/2021
MSLN • CTAG1B • HLA-A
|
HLA-A positive • MSLN positive
|
multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Phase 2
Chinese Academy of Medical Sciences
Completed
Last update posted :
02/02/2021
Initiation :
08/01/2015
Primary completion :
12/01/2018
Completion :
06/01/2019
HER-2
|
Herceptin (trastuzumab) • docetaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
Phase 1
Pieris Pharmaceuticals, Inc.
Recruiting
Last update posted :
02/01/2021
Initiation :
09/28/2017
Primary completion :
05/01/2021
Completion :
09/01/2021
HER-2 • TNFRSF9
|
cinrebafusp alfa (PRS-343)
Phase 1
Ruijin Hospital
Recruiting
Last update posted :
01/29/2021
Initiation :
08/01/2020
Primary completion :
08/01/2022
Completion :
08/01/2024
HER-2
|
HER-2 negative
|
capecitabine • AiRuiKa (camrelizumab)
Phase 2
Fudan University
Recruiting
Last update posted :
01/26/2021
Initiation :
02/01/2019
Primary completion :
01/01/2022
Completion :
01/01/2024
ALB
|
paclitaxel • docetaxel
Phase 1
Eli Lilly and Company
Completed
Last update posted :
01/20/2021
Initiation :
02/19/2016
Primary completion :
03/27/2018
Completion :
01/13/2021
AFP
|
Imfinzi (durvalumab) • Cyramza (ramucirumab)
Phase 2
Academisch Medisch Centrum - Universiteit van A...
Recruiting
Last update posted :
01/15/2021
Initiation :
05/01/2019
Primary completion :
08/01/2022
Completion :
08/01/2023
HER-2
|
HER-2 positive • HER-2 negative
|
carboplatin • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
Phase 1/2
Institut Bergonié
Recruiting
Last update posted :
01/13/2021
Initiation :
05/04/2018
Primary completion :
11/01/2021
Completion :
05/01/2022
BRAF • PD-L1 • ALK • ROS1 • MSI
|
ALK positive • ROS1 positive • ALK mutation
|
Bavencio (avelumab) • Stivarga (regorafenib)
Phase 2
University of California, Irvine
Recruiting
Last update posted :
01/08/2021
Initiation :
02/04/2020
Primary completion :
09/10/2021
Completion :
06/30/2022
PD-L1
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • cisplatin • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 2
Catalysis SL
Recruiting
Last update posted :
01/08/2021
Initiation :
10/25/2018
Primary completion :
06/01/2021
Completion :
09/01/2021
ALB
Phase 2
Shanghai Changzheng Hospital
Recruiting
Last update posted :
12/30/2020
Initiation :
07/01/2019
Primary completion :
08/31/2021
Completion :
12/31/2021
EGFR
|
EGFR amplification
|
Erbitux (cetuximab) • capecitabine • oxaliplatin • TheraCIM (nimotuzumab)
Phase 1
Millennium Pharmaceuticals, Inc.
Completed
Last update posted :
12/29/2020
Initiation :
03/28/2019
Primary completion :
12/03/2019
Completion :
12/03/2019
TP53
|
TP53 mutation
|
esomeprazole • simurosertib (TAK-931)
Phase 1/2
BioNTech SE
Not yet recruiting
Last update posted :
12/24/2020
Initiation :
09/01/2021
Primary completion :
09/01/2024
Completion :
09/01/2024
CLDN18
|
CLDN18.2 positive
|
BNT141
Phase 2
Duke University
Active, not recruiting
Last update posted :
12/24/2020
Initiation :
01/11/2018
Primary completion :
01/22/2022
Completion :
01/22/2024
HER-2
|
HER-2 positive
|
Keytruda (pembrolizumab) • capecitabine • oxaliplatin
Phase 2
Weill Medical College of Cornell University
Recruiting
Last update posted :
12/22/2020
Initiation :
03/07/2017
Primary completion :
07/01/2021
Completion :
07/01/2021
PD-L1
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel
Phase 1a
Novita Pharmaceuticals, Inc.
Completed
Last update posted :
12/22/2020
Initiation :
12/21/2017
Primary completion :
05/07/2020
Completion :
05/07/2020
ALB
|
NP-G2-044
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/18/2020
Initiation :
07/01/2012
Primary completion :
03/01/2014
Completion :
03/01/2014
HER-2
|
elgemtumab (LJM-716)
Phase 2
Henan Cancer Hospital
Not yet recruiting
Last update posted :
12/18/2020
Initiation :
12/31/2020
Primary completion :
12/31/2021
Completion :
12/31/2022
HER-2
|
HER-2 negative
|
Abraxane (albumin-bound paclitaxel) • AiRuiKa (camrelizumab) • Teysuno (gimeracil/oteracil/tegafur)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/18/2020
Initiation :
07/01/2012
Primary completion :
04/01/2015
Completion :
04/01/2015
HER-2 • PGR
|
HR positive
|
buparlisib (BKM120) • Odomzo (sonidegib)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/17/2020
Initiation :
09/01/2013
Primary completion :
03/01/2015
Completion :
03/01/2015
HER-2
|
HER-2 overexpression
|
elgemtumab (LJM-716)
Phase 2
Samsung Medical Center
Active, not recruiting
Last update posted :
12/14/2020
Initiation :
03/26/2016
Primary completion :
12/01/2021
Completion :
12/01/2021
PD-L1 • MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase N/A
Stanford University
Suspended
Last update posted :
12/10/2020
Initiation :
09/16/2019
Primary completion :
05/01/2022
Completion :
09/01/2022
BRAF • MSI
|
BRAF V600E • MSI-H/dMMR • BRAF V600